Cargando…

PD-1 inhibitors in endometrial cancer

Detalles Bibliográficos
Autores principales:	Barroso-Sousa, Romualdo, Ott, Patrick A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739721/ https://www.ncbi.nlm.nih.gov/pubmed/29290936 http://dx.doi.org/10.18632/oncotarget.22583

Ejemplares similares

Current Landscape and Future Direction of PD-1/PD-L1 Checkpoint Inhibitors in Cancer Treatment
por: Serratì, Simona, et al.
Publicado: (2023)

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series
por: Martini, Dylan J., et al.
Publicado: (2017)

PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
por: Luke, Jason J., et al.
Publicado: (2015)

Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
por: Elias, Rawad, et al.
Publicado: (2018)

Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers
por: Sulaiman, Raed, et al.
Publicado: (2023)

Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance
por: Mamat @ Yusof, Mohd Nazzary, et al.
Publicado: (2023)

PD-1 inhibitors provide new opportunities in conversion therapy for stage IV gastric cancer
por: Liang, Han
Publicado: (2022)

Efficacy and Safety of PD-1/PD-L1 Inhibitor as Single-Agent Immunotherapy in Endometrial Cancer: A Systematic Review and Meta-Analysis
por: Mamat @ Yusof, Mohd Nazzary, et al.
Publicado: (2023)

PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade
por: Hirsch, Laure, et al.
Publicado: (2018)

Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies)
por: Ono, Ruriko, et al.
Publicado: (2019)

Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond
por: Barroso-Sousa, Romualdo, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 Pathway in Advanced, Recurrent Endometrial Cancer: A Scoping Review with SWOT Analysis
por: Johnson, Racheal Louise, et al.
Publicado: (2023)

(18)F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab
por: Seban, Romain-David, et al.
Publicado: (2021)

Controversies in the Management of Endometrial Cancer
por: Hernandez, Enrique, et al.
Publicado: (2010)

Immunohistochemical Markers in Endometrial Cancer
por: Mais, Valerio, et al.
Publicado: (2021)

Towards individualisation of treatment in endometrial cancer
por: Taylor, S E, et al.
Publicado: (2012)

Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer
por: Mo, Zhongfu, et al.
Publicado: (2016)

PD-L1 expression associated with better response to EGFR tyrosine kinase inhibitors
por: Rosell, Rafael, et al.
Publicado: (2015)

Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice
por: Campesato, Luís Felipe, et al.
Publicado: (2015)

High-potency PD-1/PD-L1 degradation induced by Peptide-PROTAC in human cancer cells
por: Dai, Meng-Yuan, et al.
Publicado: (2022)

Evidence to date: talazoparib in the treatment of breast cancer
por: Exman, Pedro, et al.
Publicado: (2019)

Clinical Implication of PD-L1 Expression in Patients with Endometrial Cancer
por: Kim, Yeorae, et al.
Publicado: (2023)

Genetic biomarkers for PD-1/PD-L1 blockade therapy
por: Kataoka, Keisuke, et al.
Publicado: (2016)

Role of the PD-1 and PD-L1 axis in COVID-19
por: R Bonam, Srinivasa, et al.
Publicado: (2022)

The impact of single agent PD-1 or PD-L1 inhibition on advanced endometrial cancers: meta-analysis
por: Kok, P.-S., et al.
Publicado: (2022)

New Insights into Breast and Endometrial Cancers
por: Miki, Yasuhiro
Publicado: (2020)

Recent Advances in Endometrial Cancer Management
por: Di Donato, Violante, et al.
Publicado: (2023)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

MR staging of endometrial cancer: needed or wanted?
por: Spencer, John A, et al.
Publicado: (2008)

PD-L1/PD-1: new kid on the “immune metabolic” block
por: Qorraj, Mirjeta, et al.
Publicado: (2017)

Quantitative spatial profiling of PD-1/PD-L1 interaction in patients with cancer
por: Hakozaki, Taiki
Publicado: (2023)

New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series
por: Lambertini, Matteo, et al.
Publicado: (2019)

Emerging concept of tailored lymphadenectomy in endometrial cancer
por: Sakuragi, Noriaki
Publicado: (2012)

New Strategies for Endometrial Cancer Detection and Management
por: Paleari, Laura
Publicado: (2023)

Immunohistochemical Markers in Endometrial Cancer: Latest Updates
por: Mais, Valerio, et al.
Publicado: (2023)

PD‐1/PD‐L1 co‐location: A novel biomarker for immunotherapy response in non‐small cell lung cancer
por: Diao, Xiayao, et al.
Publicado: (2022)

Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy
por: Hu, Weixian
Publicado: (2019)

Lenvatinib/Pembrolizumab as second line treatment for advanced melanoma patients refractory to programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors
por: Ferrucci, Pier Francesco
Publicado: (2023)

PD‐1 Pandemonium at the American Association for Cancer Research Annual Meeting
por: Bates, Susan E.
Publicado: (2019)

Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
por: Cheng, Chao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8djf3hkmtkgi5c6fga18nhp22k